5[1]NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001,285:785-795.
6[2]Weinstein RS. True strength. J Bone Miner Res 2000,15:621-625.
7[3]Chesnut Ⅲ CH, Rosen CJ for the Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001,16:2163-2172.
8[4]Marcus R, Wong M, Heath Ⅲ H, et al. Antiresorptive treatment of posrmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002,23:16-37.
9[5]Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001,19:331-337.
10[6]Cummings SR, Karpf DB, Harris F, et al. Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002,112: 282-289.
6Suzuki K, Kurose T, Takizawa M, et al. Osteoclastic func- tion is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibito- ry factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density [J ].Diabetes Res Clin Pract, 2005, 68(2): 117-125.
7R kel A, Sheehy O, Rahme E, et al. Osteoporosis among patients with type 1 and type 2 diabetes[J].Diabetes Me- tab,2008,34(3): 93-105.
9Murray M A, Slater H, Clarke K K, et al. Fracture inci- dence in adolescent girls with type 1 diabetes (din) and relation to age at onset, metabolic control bone. charac- teristics, and bone turnover[J].Bone,2007,40(6):S68-S69.
10Melton L J, Leibson C L, Achenbach S J, et al. Fracture risk in type 2 diabetes: update of a population-based study[J].J Bone Miner Res, 2008,23(8):1334-1342.